541 results on '"Bernasconi, Paolo"'
Search Results
102. Alternative Splicing of hTERT Exon 7 in AML: Biological Fuction and Prognostic Significance
103. Can Allo-HSCT Improve the Poor Clinical Outcome of the “Internal Tandem Duplication” of the FLT3 Gene?
104. Gestione e vigilianza di gruppi bancari multinazionali
105. FuseFISH: Robust Detection of Transcribed Gene Fusions in Single Cells
106. Do Unexpected and Cryptic FISH Lesions Of Chromosomally Normal MDS Patients Have Any Prognostic Relevance?
107. Do Leukemic Cells and Mesenchymal Stem Cells (MSCs) From AML Patients Share The Same Chromosomal Defect? A Cytogenetics, FISH and aCGH/Snpa Study
108. Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a PCM1-JAK2 Fusion Gene
109. Human Telomerase Reverse Transcriptase (hTERT): A New Potential Prognostic Marker in AML?
110. Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated with t(8;9)(p22;p24) and PCM1-JAK2 Fusion Gene.
111. Late Relapse in Leukemia: Does the Niche Matter?
112. Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase-FISH
113. Monosomal Karyotype in MDS and Secondary AML: Do Autosomal Monosomies Have the Same Poor Prognostic Impact As Monosomy 5 and 7?
114. Do FISH Lesions Have Any Role in the Pathogenesis and Outcome of Chromosomally Normal MDS?
115. Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy,
116. CpG Oligonucleotide Combined with Interleukin-2 Reveals Unexpected Chromosomal Lesions In B-CLL
117. Dose Changing and Discontinuation of Imatinib In Patients Affected by Philadelphia Positive Chronic Myeloid Leukemia: a Longitudinal Analysis, a Single Centre Experience.
118. FISH reveals chromosomal abnormalities in 41 Patients with Systemic Amyloidosis (AL).
119. correspondence: BCL3 translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance
120. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement
121. Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at PML and RARA loci
122. Validation of cytogenetic-based risk stratification in primary myelofibrosis
123. Erfahrungen aus der Sicht zweier Klassenlehrer der Fourierschule 1/93
124. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma
125. Chromosomal Abnormalities and TET2 Involvement in Therapy-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemias (t-AML).
126. FISH Reveals Abnormalities of Unsuspected Regions in Chromosomally Normal De Novo Myelodysplastic Syndromes (MDS).
127. Interferon alpha-2b as therapy for patients with Ph‘-positive chronic myelogenous leukemia
128. VOD Patient Case Forum: Percorsi interattivi sul danno endoteliale nei pazienti sottoposti a TCSE.
129. Reduced Intensity Conditioning with Thiotepa and Fludarabine for Allogeneic Transplantation: Evidence for Low Toxicity and Long-Lasting Disease Control in MDS with Low/Intermediate-1 IPSS Score and in AML from MDS in Complete Remission.
130. Searching for Amplification of Chromosome 5 Segments by Molecular Cytogenetics in 9 Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS)/(AML) Patients with Apparent Monosomy 5
131. A Complex T(10;11) MLL-AF10 Translocation with Duplication of the Rearranged Chromosome 10 in a Patient Affected with An AML M2
132. Prognostic Significance of EVI1 Defects in MDS/AML with 3q21q26 Abnormalities.
133. Bortezomib with HIG-Dose Dexamethasone as First Line Therapy in Patients with Multiple Myeloma Candidates to High-Dose Therapy.
134. Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
135. Targeting ubiquitin in cancers
136. Fluorescence In Situ Hybridization (FISH) Reveals Unexpected Cryptic Chromosome 11 Defects in MDS/AML Patients.
137. Chromosomal Evolution in B-Cell Chronic Lymphocytic Leukemia (B-CLL).
138. Fluorescence In Situ Hybridisation (FISH) To Reveal Isochromosome 7q, i(7)(q10), in Hepatosplenic T-Cell Lymphoma (HSTCL).
139. Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation as a Late Complication of Chronic Graft-versus-Host Disease
140. Molecular Genetics of Acute Myeloid Leukemia
141. Prognostic Significance of High FLT3 Expression Levels in Twenty-Six MDS Patients Examined at Diagnosis and during Disease Outcome.
142. Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. A Study by the GIMEMA Working Party on CML. On Behalf of GWP on CML.
143. Evolution of a True B-Cell Chronic Lymphocytic Leukaemia (B-CLL) in a Diffuse Immunocytoma after Treatment with Fludarabine.
144. The Relationship between the Immunophenotypic Profile and Cytogenetic Abnormalities in Acute Myeloid Leukemia.
145. High Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: Comparison of Four Preparative Regimens.
146. A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.
147. Interphase Fuorescence In Situ Hybridisation (iFISH) To Detect Cryptic Chromosome Defects in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL).
148. Human Metapneumovirus Infection in Adult Patients after Allogeneic Hemopoietic Stem Cell Transplantation.
149. The Effect of Transfusion Dependency and Secondary Iron Overload on Survival of Patients with Myelodysplastic Syndrome.
150. Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.